Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP
: Lahdenpohja S, Rajala N, Helin JS, Haaparanta-Solin M, Solin O, López-Picón FR, Kirjavainen A
Publisher: ACS Publisher
: 2020
: ACS Chemical Neuroscience
: ACS Chemical Neuroscience
: ACS Chem Neurosci
: 11
: 13
: 2009
: 2018
: 10
: 1948-7193
: 1948-7193
DOI: https://doi.org/10.1021/acschemneuro.0c00313
: https://research.utu.fi/converis/portal/detail/Publication/49232153
Cannabinoid receptor 1 (CB1R) controls various physiological and pathological conditions, including memory, motivation, and inflammation, and is thus an interesting target for positron emission tomography (PET). Herein, we report a ruthenium-mediated radiolabeling synthesis and preclinical evaluation of a new CB1R specific radiotracer, [18F]FPATPP. [18F]FPATPP was produced with 16.7 ± 5.7% decay-corrected radiochemical yield and >95 GBq/μmol molar activity. The tracer showed high stability, low defluorination, and high specific binding to CB1Rs in mouse brain.
